1. Home
  2. VET vs NNNN Comparison

VET vs NNNN Comparison

Compare VET & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vermilion Energy Inc.

VET

Vermilion Energy Inc.

HOLD

Current Price

$8.26

Market Cap

1.3B

Sector

Energy

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$35.22

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VET
NNNN
Founded
1994
2021
Country
Canada
Germany
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
VET
NNNN
Price
$8.26
$35.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.5M
33.5K
Earning Date
11-05-2025
04-28-2026
Dividend Yield
4.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
$1,445,514,003.00
$6,920,153.00
Revenue This Year
$11.40
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$596.62
Revenue Growth
30.48
N/A
52 Week Low
$5.14
$5.18
52 Week High
$10.49
$55.65

Technical Indicators

Market Signals
Indicator
VET
NNNN
Relative Strength Index (RSI) 48.46 54.20
Support Level $7.76 $30.15
Resistance Level $8.64 $35.40
Average True Range (ATR) 0.25 3.55
MACD -0.01 -0.09
Stochastic Oscillator 57.06 57.12

Price Performance

Historical Comparison
VET
NNNN

About VET Vermilion Energy Inc.

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: